The Effect of NLP Individual Psychotherapy On The Reduction Of Symptom Of Depression, Anxiety, Stress and Improving Quality of Life and Control of proceeding Disease on RRMS Patients

Evaluation of effectiveness of Neuro Linguistic Programming individual treatment on depression, anxiety, stress, quality of life and the course and severity of the disease in patients with relapsing-remitting multiple-sclerosis (RRMS): a Randomized Clinical Trial

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

IRCT

Registry ID

IRCT20171217037917N1

Enrollment

Registered

2018-10-30

Start date

2018-02-20

Completion date

Unknown

Last updated

2019-01-14

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Condition 1: Multiple sclerosis. Condition 2: Anxiety. Condition 3: Depression. Condition 4: Stress. Multiple sclerosis

Interventions

Intervention 1: Experimental or intervention group: 30 patients, One hour individual therapy sessions, intervention: Neuro Linguistic Programming Therapy, 45 sessions: first 16 sessions are weekly, 18

Eligibility

Sex/Gender

All

Age

20 Years to 40 Years

Inclusion criteria

Inclusion criteria: Diagnosis of MS based on McDonald criteria by neurologist Type of MS (relapsing-remitting) Age range (20 to 40) years old Residing in Tehran Having the consent and commitment to attend the course of treatment Diagnosis of stress, anxiety and depression on DSM criteria by psychiatrist using of first-line drugs for the MS treatment: Interferons

Exclusion criteria

Exclusion criteria: pregnancy or planning for pregnancy having any type of psychotherapy session during this research having history of Hospitalization due to psychiatric disorders diagnosis of other psychiatric disorders according to DSM by a psychiatrist having cancer having diabetes Other diseases of the nervous system other than multiple sclerosis

Design outcomes

Primary

Measure	Time frame
Level of stress. Timepoint: pre test and 6,12,18 months after start of treatment, and 24 months after first intervention as post test. Method of measurement: DASS Questionnaire (Depression, Anxiety, Stress).;Level of anxiety. Timepoint: pre test and 6,12,18 months after start of treatment, and 24 months after first intervention as post testT. Method of measurement: DASS Questionnaire (Depression, Anxiety, Stress).;Level of depression. Timepoint: pre test and 6,12,18 months after start of treatment, and 24 months after first intervention as post test. Method of measurement: DASS Questionnaire (Depression, Anxiety, Stress).;Disability Status. Timepoint: pre test and 6,12,18 months after start of treatment, and 24 months after first intervention as post test. Method of measurement: Kurtzke Expanded Disability Status Scale (EDSS).;Quality of life. Timepoint: pre test and 6,12,18 months after start of treatment, and 24 months after first intervention as post test. Method of measurement: Multiple Sclerosis Quality of Life-54 (MSQOL-54) questionnaire.;Course of MS disease. Timepoint: pre test and 6,12,18 months after start of treatment, and 24 months after first intervention as post test. Method of measurement: MRI (Magnetic Resonance Imaging).	—

Measure

Time frame

Level of stress. Timepoint: pre test and 6,12,18 months after start of treatment, and 24 months after first intervention as post test. Method of measurement: DASS Questionnaire (Depression, Anxiety, Stress).;Level of anxiety. Timepoint: pre test and 6,12,18 months after start of treatment, and 24 months after first intervention as post testT. Method of measurement: DASS Questionnaire (Depression, Anxiety, Stress).;Level of depression. Timepoint: pre test and 6,12,18 months after start of treatment, and 24 months after first intervention as post test. Method of measurement: DASS Questionnaire (Depression, Anxiety, Stress).;Disability Status. Timepoint: pre test and 6,12,18 months after start of treatment, and 24 months after first intervention as post test. Method of measurement: Kurtzke Expanded Disability Status Scale (EDSS).;Quality of life. Timepoint: pre test and 6,12,18 months after start of treatment, and 24 months after first intervention as post test. Method of measurement: Multiple Sclerosis Quality of Life-54 (MSQOL-54) questionnaire.;Course of MS disease. Timepoint: pre test and 6,12,18 months after start of treatment, and 24 months after first intervention as post test. Method of measurement: MRI (Magnetic Resonance Imaging).

—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactBahare Pourkiani

Tehran University of Medical Sciences

bahare.pourkiani@yahoo.com+98 21 2219 0588

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026